Publications by authors named "Marianne K O Grant"

Carfilzomib (CFZ), a second-generation proteasome inhibitor, is a key treatment for multiple myeloma (MM), but its use is associated with significant cardiovascular adverse events (CVAEs), including heart failure and hypertension. Endothelial dysfunction is believed to contribute to these CVAEs. Building on our previous findings that CFZ induces endothelial toxicity and that canagliflozin protects against CFZ-induced endothelial apoptosis, this study aimed to evaluate CFZ-induced endoplasmic reticulum (ER) stress and autophagy in endothelial and MM cells, as well as the impact of canagliflozin on these processes and its impact on the anticancer effects of CFZ in MM cells.

View Article and Find Full Text PDF
Article Synopsis
  • * After one week of DOX treatment, there was a significant reduction in thymus weight and notable alterations in T cell populations, indicating early immune system effects, along with changes in gene expression linked to immune function and senescence.
  • * Five weeks post-treatment, some recovery was observed with an increase in thymus weight and shifts in T cell subsets, but also revealed decreases in specific memory T cells, pointing towards long-term changes in immune response following DOX exposure.
View Article and Find Full Text PDF

Irreversible cardiotoxicity limits the clinical application of doxorubicin (DOX). DOX-induced cardiotoxicity has been associated with induction of senescence and activation of the p38 MAPK pathway. Losmapimod (LOSM), an orally active p38 MAPK inhibitor, is an anti-inflammatory agent with cardioprotective effects.

View Article and Find Full Text PDF

Cancer survivors may experience long-term cardiovascular complications due to chemotherapeutic drugs such as doxorubicin (DOX). The exact mechanism of delayed DOX-induced cardiotoxicity has not been fully elucidated. Sex is an important risk factor for DOX-induced cardiotoxicity.

View Article and Find Full Text PDF

Carfilzomib (CFZ) is a proteasome inhibitor approved for relapsed/refractory multiple myeloma (MM) but its clinical use is limited by cardiovascular toxicity. The mechanisms of CFZ-induced cardiovascular toxicity are not fully understood but endothelial dysfunction may be a common denominator. Here, we first characterized the direct toxic effects of CFZ on endothelial cells (HUVECs and EA.

View Article and Find Full Text PDF

Doxorubicin (DOX), a chemotherapeutic drug, induces senescence and increases the secretion of senescence-associated secretory phenotype (SASP) in endothelial cells (ECs), which contributes to DOX-induced inflammaging. Metformin, an anti-diabetic drug, demonstrates senomorphic effects on different models of senescence. However, the effects of metformin on DOX-induced endothelial senescence have not been reported before.

View Article and Find Full Text PDF

Sex is a salient risk factor in the development of doxorubicin-induced cardiotoxicity. Sex differences in the heart's ability to respond to hypertrophic stimuli in doxorubicin-exposed animals have not been reported. We identified the sexual dimorphic effects of isoproterenol in mice pre-exposed to doxorubicin.

View Article and Find Full Text PDF

Childhood cancer survivors have a high risk for premature cardiovascular diseases, mainly due to cardiotoxic cancer treatments such as doxorubicin (DOX). Psychosocial stress is a significant cardiovascular risk factor and an enormous burden in childhood cancer survivors. Although observational studies suggest that psychosocial stress is associated with cardiovascular complications in cancer survivors, there is no translationally relevant animal model to study this interaction.

View Article and Find Full Text PDF

Doxorubicin (DOX) induces endothelial cell (EC) senescence, which contributes to endothelial dysfunction and cardiovascular complications. Senolytic drugs selectively eliminate senescent cells to ameliorate senescence-mediated pathologies. Previous studies have demonstrated differences between immortalized and primary EC models in some characteristics.

View Article and Find Full Text PDF

Hypertension is the most significant risk factor for heart failure in doxorubicin (DOX)-treated childhood cancer survivors. We previously developed a two-hit mouse model of juvenile DOX-induced latent cardiotoxicity that is exacerbated by adult-onset angiotensin II (ANGII)-induced hypertension. It is still not known how juvenile DOX-induced latent cardiotoxicity would predispose the heart to pathologic stimuli that do not cause hypertension.

View Article and Find Full Text PDF

Doxorubicin (DOX) is one of the most widely used chemo-therapeutic agents in pediatric oncology. DOX elicits an inflammatory response in multiple organs, which contributes to DOX-induced adverse effects. Cancer itself causes inflammation leading to multiple pathologic conditions.

View Article and Find Full Text PDF

Cardiovascular complications have been frequently reported in cancer patients and survivors, mainly because of various cardiotoxic cancer treatments. Despite the known cardiovascular toxic effects of these treatments, they are still clinically used because of their effectiveness as anti-cancer agents. In this review, we discuss the growing body of evidence suggesting that inhibition of the cytochrome P450 1B1 enzyme (CYP1B1) can be a promising therapeutic strategy that has the potential to prevent cancer treatment-induced cardiovascular complications without reducing their anti-cancer effects.

View Article and Find Full Text PDF

Sex-related differences in cardiovascular diseases are highly complex in humans and model-dependent in experimental laboratory animals. The objective of this work was to comprehensively investigate key sex differences in the response to acute and prolonged adrenergic stimulation in C57Bl/6NCrl mice. Cardiac function was assessed by trans-thoracic echocardiography before and after acute adrenergic stimulation (a single sub-cutaneous dose of isoproterenol 10 mg/kg) in 15 weeks old male and female C57Bl/6NCrl mice.

View Article and Find Full Text PDF

Doxorubicin (DOX) is an effective chemotherapeutic agent used to treat a wide variety of malignancies. In addition to its multi-organ toxicity, DOX treatment has been shown to induce systemic inflammation in patients and experimental animals. Inflammation alters the expression of hepatic cytochrome P450 (CYP) enzymes, which play important roles in drug metabolism and DOX-induced toxicity.

View Article and Find Full Text PDF

Antibodies are commonly used to detect or isolate proteins from biological samples. Much attention has been paid to the potential for poorly-characterized antibodies to lead to misleading results, but artefacts may also occur. Here, we recount two examples of antibody-independent artefacts that have confounded the interpretation of results in our search for molecular entities associated with memory loss in Alzheimer's disease (AD).

View Article and Find Full Text PDF

Cardio-oncology is a clinical/scientific discipline which aims to prevent and/or treat cardiovascular diseases in cancer patients. Although a large number of cancer treatments are known to cause cardiovascular toxicity, they are still widely used because they are highly effective. Unfortunately, therapeutic interventions to prevent and/or treat cancer treatment-induced cardiovascular toxicity have not been established yet.

View Article and Find Full Text PDF

In a previous study, we reported that levels of two types of protein species-a type of ~55-kDa species and a type of ~15-kDa species-are elevated in the lumbar cerebrospinal fluid (CSF) of cognitively intact elderly individuals who are at risk for Alzheimer's disease (AD). These species are immunoreactive to the monoclonal antibody 6E10, which is directed against amino acids 6-10 of amyloid-β (Aβ), and their levels correlate with levels of total tau and tau phosphorylated at Thr181. In this study, we investigated the molecular composition of these AD-related proteins using immunoprecipitation (IP)/Western blotting coupled with IP/mass spectrometry.

View Article and Find Full Text PDF

Doxorubicin (DOX) is a chemotherapeutic agent that has been reported to cause nephrotoxicity in rodent models and to a lesser degree in cancer patients. Female rodents have been shown to be protected against several features of DOX-induced nephrotoxicity. Nevertheless, the underlying mechanisms of this sexual dimorphism are not fully elucidated.

View Article and Find Full Text PDF

Background: There is inconclusive evidence about the role of sex as a risk factor for doxorubicin (DOX)-induced cardiotoxicity. Recent experimental studies have shown that adult female rats are protected against DOX-induced cardiotoxicity. However, the mechanisms of this sexual dimorphism are not fully elucidated.

View Article and Find Full Text PDF

The accumulation of amyloid-β (Aβ) as amyloid fibrils and toxic oligomers is an important step in the development of Alzheimer's disease (AD). However, there are numerous potentially toxic oligomers and little is known about their neurological effects when generated in the living brain. Here we show that Aβ oligomers can be assigned to one of at least two classes (type 1 and type 2) based on their temporal, spatial, and structural relationships to amyloid fibrils.

View Article and Find Full Text PDF
Article Synopsis
  • Xanomeline is a distinctive agonist targeting muscarinic receptors, specifically M(1) and M(4) subtypes, with unique binding properties that allow it to activate these receptors for an extended period after washout.
  • Research showed that when CHO cells with the M(1) receptor were pretreated with xanomeline, the inhibition of radiolabeled NMS binding shifted from a simple pattern to a more complex one, indicating strong and durable binding effects.
  • The prolonged presence of xanomeline reduced both receptor activity and binding capacities, suggesting that its long-term impacts stem from receptor down-regulation rather than just receptor internalization.
View Article and Find Full Text PDF
Article Synopsis
  • Xanomeline uniquely binds to M1 and M3 muscarinic receptors at both orthosteric and allosteric sites, leading to a decrease in receptor response after the agonist is removed.
  • In experiments, Chinese hamster ovary cells were exposed to xanomeline and other agonists, with results showing that xanomeline alters radioligand binding and receptor function over time.
  • The findings suggest that xanomeline's lasting effects on receptor activity are linked to its binding at the allosteric site and require receptor activation to occur.
View Article and Find Full Text PDF
Article Synopsis
  • Xanomeline is identified as a selective agonist for M1/M4 muscarinic receptors, and its unique binding behavior at the M1 receptor has been established in previous studies.
  • The current study focuses on xanomeline's binding to the M3 receptor in CHO cells, discovering that its binding mechanism is reversible and resilient against washing, leading to a functional response.
  • Long-term exposure to xanomeline changes the binding profile of certain ligands and reduces the overall number of M3 receptors on the cell surface, suggesting its binding has significant, time-dependent effects on receptor regulation.
View Article and Find Full Text PDF
Article Synopsis
  • A series of xanomeline analogs were created to test their binding effectiveness at the M(1) muscarinic acetylcholine receptor, focusing on modifications to the O-hexyl chain of xanomeline.
  • The study found several new compounds that bind more strongly and persistently to the M(1) receptor than xanomeline itself, suggesting that these interactions may involve both hydrophobic and ionic components.
  • A model is proposed to explain how these binding interactions work, shedding light on the structural reasons behind the wash-resistant binding and the long-lasting effects of xanomeline-based drugs.
View Article and Find Full Text PDF
Article Synopsis
  • - Xanomeline uniquely binds to the M1 muscarinic acetylcholine receptors by sticking not only to the main binding site but also to a secondary site, leading to prolonged receptor activation even after the drug is washed out.
  • - A study showed that a 1-minute exposure to xanomeline caused a lasting decrease in [3H]N-methylscopolamine (NMS) binding, indicating a wash-resistant activation of the receptor.
  • - After washing the cells and waiting 24 hours, the effects of xanomeline changed, revealing a two-phase binding curve that indicated a new, more potent binding state and suggesting that the initial brief exposure could lead to delayed receptor changes like desensitization or internal
View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessionhhv1e7v1cevqj606tjv84d71ilo83vav): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once